Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III EGF cancer vaccine in stage IV NSCLC
2013-005335-25Phase 3Terminated
- Sponsor
- Bioven
- Start
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human EGF-rP64K + Montanide ISA 51 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bioven. Primary endpoint: Overall survival. Started Mar 2014; status: terminated.
02
Drugs
recombinant human EGF-rP64K + Montanide ISA 51
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-005335-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005335-25.